SCHEMBL1499587

SCHEMBL1499587

COc1ccc(C(=O)Nc2ccc(Nc3cccc(C(=O)NCCC(C)C)c3)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.58
KCNK9 Q9NPC2 1/20 0.54
PAX8 Q06710 1/20 0.53
KCNK3 O14649 1/20 0.53
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
NR1H4 Q96RI1 1/20 0.53
GAA P10253 1/20 0.53
NPC1 O15118 5/20 0.52
RAB9A P51151 5/20 0.52
TP53 P04637 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
ALOX15 P16050 1/20 0.52
ALDH1A1 P00352 1/20 0.52
PKM P14618 1/20 0.52
MAPT P10636 1/20 0.52
BCHE P06276 1/20 0.51
CASP3 P42574 2/20 0.50
SENP7 Q9BQF6 2/20 0.50
SENP8 Q96LD8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1499593 0.95 KCNK9 (0.61) NAMPTKCNK9PAX8KCNK3KMT2A
SCHEMBL1499289 0.94 KCNK9 (0.59) NAMPTKCNK9PAX8KCNK3KMT2A
SCHEMBL29973699 0.94 KCNK9 (0.59) NAMPTKCNK9PAX8KCNK3KMT2A
SCHEMBL1499346 0.93 NPC1 (0.59) NAMPTKCNK9KCNK3KMT2AMEN1
SCHEMBL1499493 0.91 NPC1 (0.62) NAMPTKMT2AMEN1GAANPC1
SCHEMBL29973955 0.91 KCNK9 (0.61) NAMPTKCNK9PAX8KCNK3KMT2A
SCHEMBL1499527 0.91 KCNK9 (0.61) NAMPTKCNK9PAX8KCNK3KMT2A
SCHEMBL17833837 0.88 NPC1 (0.53) NAMPTPAX8KMT2AMEN1NR1H4
SCHEMBL1499500 0.87 MTNR1B (0.57) NAMPTKMT2AGAANPC1RAB9A
SCHEMBL1499474 0.87 HPGD (0.62) NAMPTGAANPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011509280-A 2011-03-24 JP claimed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 EP claimed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 WO claimed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 WO claimed
EP-3536691-B1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2022-10-05 EP disclosed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 EP disclosed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 EP disclosed
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-19 US disclosed
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-19 US disclosed
US-10538485-B2 Compounds for use as therapeutic agents affecting P53 expression and/or activity ABIVAX (FR) 2020-01-21 US disclosed
EP-3536691-A1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) 2019-09-11 EP disclosed
EP-3536691-A1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) 2019-09-11 EP disclosed
WO-2012131656-A2 COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY SOCIÉTÉ SPLICOS (FR) 2012-10-04 WO disclosed
EP-2505198-A1 Compounds for use as therapeutic agents affecting p53 expression and/or activity Société Splicos (FR) 2012-10-03 EP disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 US disclosed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 EP disclosed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 WO disclosed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies RBM17, RBM22, PRPF40A NAMPT 571/4885KCNK9 4726/4885PAX8 4128/4885
US-10538485-B2 Compounds for use as therapeutic agents affecting P53 expression and/or activity TP53, TP53BP1, BCOR NAMPT 2989/4885KCNK9 3309/4885PAX8 2450/4885
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, SF3B5, SF3B1 NAMPT 3628/4885KCNK9 3519/4885PAX8 2005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.